BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24898076)

  • 1. Patient with Gorlin syndrome and metastatic basal cell carcinoma refractory to smoothened inhibitors.
    Zhu GA; Li AS; Chang AL
    JAMA Dermatol; 2014 Aug; 150(8):877-9. PubMed ID: 24898076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
    Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
    Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
    Meani RE; Lim SW; Chang AL; Kelly JW
    Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced treatment for basal cell carcinomas.
    Atwood SX; Whitson RJ; Oro AE
    Cold Spring Harb Perspect Med; 2014 Jul; 4(7):a013581. PubMed ID: 24985127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
    Danial C; Sarin KY; Oro AE; Chang AL
    Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449.
    Goldberg LH; Landau JM; Moody MN; Kazakevich N; Holzer AM; Myers A
    Arch Dermatol; 2011 Jul; 147(7):839-41. PubMed ID: 21422324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
    Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
    Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
    Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K
    J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678
    [No Abstract]   [Full Text] [Related]  

  • 13. Hedgehog pathway inhibition and the race against tumor evolution.
    Atwood SX; Chang AL; Oro AE
    J Cell Biol; 2012 Oct; 199(2):193-7. PubMed ID: 23071148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sonidegib phosphate: new approval for basal cell carcinoma.
    Tibes R
    Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoothened inhibitors in the treatment of advanced basal cell carcinomas.
    Kunstfeld R
    Curr Opin Oncol; 2014 Mar; 26(2):184-95. PubMed ID: 24469022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.
    Kuonen F; Huskey NE; Shankar G; Jaju P; Whitson RJ; Rieger KE; Atwood SX; Sarin KY; Oro AE
    J Invest Dermatol; 2019 Jul; 139(7):1439-1448. PubMed ID: 30707899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vismodegib resistance in basal cell carcinoma: not a smooth fit.
    Ridky TW; Cotsarelis G
    Cancer Cell; 2015 Mar; 27(3):315-6. PubMed ID: 25759014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GDC-0449--targeting the hedgehog signaling pathway.
    Dierks C
    Recent Results Cancer Res; 2010; 184():235-8. PubMed ID: 20072843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
    Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
    Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.